Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
95
days
Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs
AuthorsXuemin Lu; Xin Lu
AffiliationsDepartment of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Tumor Microenvironment and Metastasis Program, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA
75
days
The case for AI-driven cancer clinical trials – The efficacy arm in silico
AuthorsLikhitha Kolla; Fred K. Gruber; Omar Khalid; Colin Hill; Ravi B. Parikh
AffiliationsPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; GNS Healthcare, Somerville, MA, USA
77
days
The potential of AI in cancer care and research
AuthorsNorman E. Sharpless; Anthony R. Kerlavage
AffiliationsNational Cancer Institute, Bethesda, MD, United States of America
85
days
Data-driven approaches to advance research and clinical care for pediatric cancer
AuthorsAlexander M. Gout; Sasi Arunachalam; David B. Finkelstein; Jinghui Zhang
AffiliationsDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
27
days
Pediatric low-grade gliomas: How modern biology reshapes the clinical field
AuthorsGuillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A. Segal; Rameen Beroukhim; Keith L. Ligon; Jacques Grill; Mark W. Kieran
AffiliationsDepartment of Cancer Biology, Dana–Farber Cancer Institute, Boston, MA, USA; Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Center for Molecular Oncologic Pathology, Dana–Farber Cancer Institute, Boston, MA, USA; Division of Pediatric Hematology and Oncology, Dana–Farber Cancer Institute, Boston, MA, USA; Boston Children's Hospital, Boston, MA, USA; Department of Neurobiology, Harvard Medical School, Boston, MA, USA
118
days
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
AuthorsMatteo Santoni; Francesco Pantano; Consuelo Amantini; Massimo Nabissi; Alessandro Conti; Luciano Burattini; Alice Zoccoli; Rossana Berardi; Giorgio Santoni; Giuseppe Tonini; Daniele Santini; Stefano Cascinu
AffiliationsMedical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, via Conca 71, 60126 Ancona, Italy; Department of Medical Oncology, Campus Bio-Medico University of Rome, via Alvaro del Portillo 200, 00128 Rome, Italy; School of Pharmacy, Section of Experimental Medicine, University of Camerino, via Madonna delle Carceri 9, 62032 Camerino, Italy; Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Clinica di Urologia, Polytechnic University of the Marche Region, via Conca 71, 60126 Ancona, Italy
100
days
MUC1: A novel metabolic master regulator
AuthorsKamiya Mehla; Pankaj K. Singh
AffiliationsThe Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Genetic Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA
43
days
The NF-Y/p53 liaison: Well beyond repression
AuthorsCarol Imbriano; Nerina Gnesutta; Roberto Mantovani
AffiliationsDipartimento di Biologia, Università degli Studi di Modena e Reggio Emilia, Via Campi 213/d, 41100 Modena, Italy; Dipartimento di Scienze Biomolecolari e Biotecnologie, Università degli Studi di Milano, Via Celoria 26, 20133, Milano, Italy
35
days
Randomized trials of high dose chemotherapy for breast cancer
AuthorsKaren H Antman
AffiliationsColumbia University, Herbert Irving Comprehensive Cancer Center, MHB 6N 435, 177 Ft. Washington Avenue, New York City, NY 10032,USA
77
days
A new family of IKK-related kinases may function as IκB kinase kinases
AuthorsRobert T Peters; Tom Maniatis
AffiliationsHarvard University, Department of Molecular and Cellular Biology, 7 Divinity Ave., Cambridge, MA 02138, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days